Literature DB >> 7718965

Guillain-Barré syndrome following fulminant viral hepatitis A.

S Ono1, K Chida, T Takasu.   

Abstract

Guillain-Barré syndrome (GBS) developed soon after the onset of acute viral hepatitis A (HA) in a 62-year-old man. GBS associated with HA is extremely rare, even though HA is common. In a review of case reports the clinical features of GBS following HA could be summarized as follows: 1) Most of the patients are men. 2) GBS develops within 14 days after the onset of HA. 3) Facial nerve palsy is frequently present. 4) Proprioception is likely impaired in addition to superficial sensation. 5) The outcome of neuropathic symptoms is uniformly good, regardless of the degree of liver dysfunction as evaluated on the basis of alanine aminotransferase levels. These findings indicate that GBS following HA essentially does not differ from typical GBS.

Entities:  

Mesh:

Year:  1994        PMID: 7718965     DOI: 10.2169/internalmedicine.33.799

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  5 in total

1.  A case of acute motor and sensory axonal neuropathy following hepatitis a infection.

Authors:  Yoon-Sik Jo; Sang-Don Han; Jin-Yong Choi; Ick Hee Kim; Yong-Duk Kim; Sang-Jun Na
Journal:  J Korean Med Sci       Date:  2013-11-26       Impact factor: 2.153

2.  Anti-glycolipid GM2-positive Guillain-Barre syndrome due to hepatitis E infection.

Authors:  S Cronin; R McNicholas; E Kavanagh; V Reid; K O'Rourke
Journal:  Ir J Med Sci       Date:  2010-11-10       Impact factor: 1.568

3.  Guillain-Barré syndrome following acute viral hepatitis A.

Authors:  Deepak Menon; Sujit Abajirao Jagtap; Muralidharan D Nair
Journal:  J Neurosci Rural Pract       Date:  2014-04

Review 4.  Guillian Barré syndrome--recent advances.

Authors:  V V Vedanarayanan; V Chaudhry
Journal:  Indian J Pediatr       Date:  2000-09       Impact factor: 5.319

5.  Fulminant guillain-barré syndrome mimicking cerebral death following acute viral hepatitis a.

Authors:  Bong-Hui Kang; Kwang-Kuk Kim
Journal:  J Clin Neurol       Date:  2007-06-20       Impact factor: 3.077

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.